In this episode, Jyoti D. Patel, MD, and Ani Balmanoukian, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising results in PD-L1-positive NSCLC. The episode includes a review of phase II data on the use of tiragolumab plus atezolizumab in NSCLC, the use of PD-L1 as a marker of response, the potential role of anti-TIGIT therapies in solid tumors, and ongoing trials in lung cancer including SKYSCRAPER-01, SKYSCRAPER-02, SKYSCRAPER-03, and SKYSCRAPER-05. Presenters:Jyoti D. Patel, MDProfessor of MedicineDivision of Hematology and OncologyMedical Director for Thoracic OncologyAssistant Director for Clinical ResearchAssociate Vice Chair of Clinical ResearchDepartment of MedicineRobert H. Lurie Comprehensive Cancer CenterNorthwestern UniversityChicago, Illinois Ani Balmanoukian, MDDirector of Thoracic OncologyMedical OncologyThe Angeles Clinic and Research Institute, a Cedars-Sinai AffiliateLos Angeles, CaliforniaLink to the complete program, including an online text module with downloadable slidesets, ClinicalThought commentaries, and an additional podcast on this topic:https://bit.ly/38qVCH7

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related